Cocrystal Pharma (COCP) Non Operating Income (2016 - 2026)
Cocrystal Pharma (COCP) posted Non Operating Income of $57000.0 for Q1 2026, up 3.64% sequentially from $55000.0 in Q4 2025, and up 42.5% YoY from $40000.0 in Q1 2025.
Cocrystal Pharma (COCP) Non Operating Income (2016 - 2026) Analysis & Trends
Cocrystal Pharma has reported Non Operating Income for 11 years, with the latest figure at $57000.0 in Q1 2026.
- Quarterly Non Operating Income rose 42.5% year-over-year to $57000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205000.0 (down 3.3% YoY) and the FY2025 annual result came in at $188000.0, down 49.73% from the prior year.
- Non Operating Income advanced to $57000.0 in Q1 2026 per COCP's latest filing, from $55000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $278000.0 in Q3 2023 and troughed at -$78000.0 in Q1 2023.
- A 5-year average of $74125.0 and a median of $54000.0 in 2025 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 20100.0% in 2023, down 2500.0% in 2023.
- Over 5 years, Non Operating Income stood at $1000.0 in 2022, then soared by 20100.0% to $202000.0 in 2023, then tumbled by 117.82% to -$36000.0 in 2024, then surged by 252.78% to $55000.0 in 2025, then increased by 3.64% to $57000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $57000.0, $55000.0, and $40000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | 55,000.00 |
| Sep 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 40,000.00 |
| Dec 31, 2024 | -36,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 105,000.00 |
| Mar 31, 2024 | 202,000.00 |
| Dec 31, 2023 | 202,000.00 |
| Sep 30, 2023 | 278,000.00 |
| Jun 30, 2023 | 173,000.00 |
| Mar 31, 2023 | -78,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -6,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Dec 31, 2021 | 17,000.00 |
| Sep 30, 2021 | 12,000.00 |
| Jun 30, 2021 | 7,000.00 |